Risk for Myocardial Infarction, Stroke, and Pulmonary Embolism Following COVID-19 Vaccines in Adults Younger Than 75 Years in France.

ABSTRACT:

Background

The BNT162b2 (Pfizer-BioNTech) vaccine has been shown to be safe with regard to risk for severe cardiovascular events (such as myocardial infarction [MI], pulmonary embolism [PE], and stroke) in persons aged 75 years or older. Less is known about the safety of other COVID-19 vaccines or outcomes in younger populations.

Objective

To assess short-term risk for severe cardiovascular events (excluding myocarditis and pericarditis) after COVID-19 vaccination in France's 46.5 million adults younger than 75 years.

Design

Self-controlled case series method adapted to event-dependent exposure and high event-related mortality.

Setting

France, 27 December 2020 to 20 July 2021.

Patients

All adults younger than 75 years hospitalized for PE, acute MI, hemor

SUBMITTER: Botton J 

PROVIDER: S-EPMC9425709 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature